Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 347

Sort by

Sort Order Select

Journal Articles

Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma

Blood blood.2024024381.

https://doi.org/10.1182/blood.2024024381

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood (2024) 143 (20): 2059–2072.

https://doi.org/10.1182/blood.2023022832

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants

Blood (2023) 142 (24): 2055–2068.

https://doi.org/10.1182/blood.2023020118

Published: 2023

Includes: Supplemental data

Journal Articles

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Blood (2023) 142 (20): 1697–1707.

https://doi.org/10.1182/blood.2023020630

Published: 2023

Includes: Supplemental data

Journal Articles

Risk Factors for Joint Bleeding in Severe Hemophilia a and B: Analysis of the Community Counts Longitudinal Surveillance Cohort

Marilyn Manco-Johnson, Suchitra Acharya, Sanjay Ahuja, Meera Chitlur, Divyaswathi Citla Sridhar, Stacey Fedewa, Daniel Isaac, Roshni Kulkarni, Laura Schieve, Anjali A. Sharathkumar, Binh Le, Mike Soucie

Blood (2023) 142 (Supplement 1): 287.

https://doi.org/10.1182/blood-2023-179850

Published: 2023

Journal Articles

MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial

Nigel H. Russell, Abin Thomas, Robert Hills, Ian Thomas, Amanda Gilkes, Nuria Almuina, Sarah Burns, Lucy Marsh, Georgia Andrew, Nicholas McCarthy, Jennifer Byrne, Rob Sellar, Richard J. Kelly, Paul Cahalin, Ulrik Malthe Overgaard, Priyanka Mehta, Mike Dennis, Steve Knapper, Sylvie D Freeman

Blood (2023) 142 (Supplement 1): 830.

https://doi.org/10.1182/blood-2023-185956

Published: 2023

Journal Articles

Advancing CAR-T Therapy in Acute Lymphoblastic Leukemia: Multi-Omic Analyses of CD19-Directed CAR-T Cells Enabled By an Ex Vivo Co-Culture Platform

Mike Mattie, Marc Gillard, Monica Calderon, Sophia Do, Shruti Salunkhe, Darren Heeke, Jose Morachis, Benjamin Titz, Chorom Pak

Blood (2023) 142 (Supplement 1): 244.

https://doi.org/10.1182/blood-2023-180395

Published: 2023

Journal Articles

FAST4TMA - Rapid Hospital-Based and out-Patient ADAMTS13 Testing

Clare Martin, Ara Metjian, Bradley Lewis, Bjorn Stromsness, Mike Ero

Blood (2023) 142 (Supplement 1): 2295.

https://doi.org/10.1182/blood-2023-175041

Published: 2023

Journal Articles

Examining Racial Disparities in Multiple Myeloma Research and Treatment

Ryan Petit, Mike Cusnir

Blood (2023) 142 (Supplement 1): 7408.

https://doi.org/10.1182/blood-2023-190669

Published: 2023

Journal Articles

RNA Splicing Factor Mutations Drive Aberrant Canonical and Cryptic Circular RNA Biogenesis in Leukemia

Mike Fernandez, Meiling Jin, Qiong Jia, Yiming Wu, Kevyn Hart, Emilee Bargoma, Joseph Pangallo, Robert K. Bradley, Omar Abdel-Wahab, Zhenyu Jia, Ren-Jang Lin, Lili Wang

Blood (2023) 142 (Supplement 1): 1395.

https://doi.org/10.1182/blood-2023-174135

Published: 2023

Journal Articles

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel Russell

Blood (2023) 142 (Supplement 1): 425.

https://doi.org/10.1182/blood-2023-179033

Published: 2023

Journal Articles

Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)

Mike Mattie, Melanie Grosso, Aurelie Auguste, Denis Arnaud, Frederick L. Locke, Sattva S. Neelapu, David B. Miklos, Caron A Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jenny J. Kim, Jenny Nater, Rhine R. Shen, Jerome Galon

Blood (2023) 142 (Supplement 1): 226.

https://doi.org/10.1182/blood-2023-187574

Published: 2023

Journal Articles

Baseline Immune State and T Cell Clonal Kinetics Are Associated with Response to CAR-T Therapy in Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 223.

https://doi.org/10.1182/blood-2023-180819

Published: 2023

Journal Articles

Single-Cell RNA Sequencing of Circulating Tumor Cells in Precursor Myeloma Patients Reveals Mechanisms of Disease Dissemination

Blood (2023) 142 (Supplement 1): 872.

https://doi.org/10.1182/blood-2023-189760

Published: 2023

Journal Articles

Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction

Mike P. Agius, Laura Hevenor, N Connor Payne, Ralph Mazitschek, Hyuk-Soo Seo, Sirano Dhe-Paganon, Jun Qi, Irene M. Ghobrial

Blood (2023) 142 (Supplement 1): 3635.

https://doi.org/10.1182/blood-2023-186864

Published: 2023

Journal Articles

CAR-NK Specific Targeting of Clonal Tcrvβ Chain to Treat T-Cell Non-Hodgkin's Lymphoma

Karen E Morris, Jenna Bowman, Ji-Ann Lee, Jeffrey W Tyner, Mike Palazzolo, Brian J. Druker, Nick Lydon, Peter M Bowers, Olivia M Lucero

Blood (2023) 142 (Supplement 1): 6841.

https://doi.org/10.1182/blood-2023-189477

Published: 2023

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

NARROW

Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Risk Factors for Joint Bleeding in Severe Hemophilia a and B: Analysis of the Community Counts Longitudinal Surveillance Cohort

MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial

Advancing CAR-T Therapy in Acute Lymphoblastic Leukemia: Multi-Omic Analyses of CD19-Directed CAR-T Cells Enabled By an Ex Vivo Co-Culture Platform

FAST4TMA - Rapid Hospital-Based and out-Patient ADAMTS13 Testing

Examining Racial Disparities in Multiple Myeloma Research and Treatment

RNA Splicing Factor Mutations Drive Aberrant Canonical and Cryptic Circular RNA Biogenesis in Leukemia

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)

Baseline Immune State and T Cell Clonal Kinetics Are Associated with Response to CAR-T Therapy in Large B-Cell Lymphoma

Single-Cell RNA Sequencing of Circulating Tumor Cells in Precursor Myeloma Patients Reveals Mechanisms of Disease Dissemination

Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction

CAR-NK Specific Targeting of Clonal Tcrvβ Chain to Treat T-Cell Non-Hodgkin's Lymphoma

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only